Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131404 | 0.88 | REN (0.41) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL13132254 | 0.84 | CNR1 (0.40) | RENSLC22A12CNR1CNR2 | |
| SCHEMBL13131386 | 0.84 | PDE4A (0.40) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL14144409 | 0.83 | REN (0.42) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL4582670 | 0.83 | REN (0.42) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL91360 | 0.83 | REN (0.44) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL2809490 | 0.82 | CNR2 (0.37) | RENCNR1CNR2 | |
| SCHEMBL4602445 | 0.81 | ICMT (0.44) | RENCNR1CNR2PDE4APDE4B | |
| SCHEMBL13962817 | 0.81 | REN (0.42) | RENSLC22A12CNR1CNR2PDE4A | |
| SCHEMBL1050732 | 0.81 | REN (0.42) | RENCNR1CNR2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2008055939-A2 | PROCESS FOR PREPARING 2-ALKYL-3-HETEROCYCLYL- PROP-2-EN- 1-OL DERIVATIVES | NOVARTIS AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921069-A1 | Process for preparing 2-alkyl-3-heterocyclyl-prop-2-en-1-ols | Speedel Experimenta AG (CH) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885SLC22A12 2804/4885CNR1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.